Articles producció científica> Enginyeria Química

Adaptive metabolic pattern biomarker for disease monitoring and staging of lung cancer with liquid biopsy

  • Identification data

    Identifier: imarina:5133292
    Handle: https://hdl.handle.net/20.500.11797/imarina5133292
    Authors:
    Garcia-Algar, ManuelFernandez-Carrascal, AnaOlano-Daza, AnaGuerrini, LucaFeliu, NeusParak, Wolfgang JGuimera, RogerGarcia-Rico, EduardoAlvarez-Puebla, Ramon A
    Abstract:
    In this manuscript, we demonstrate the applicability of a metabolic liquid biopsy for the monitoring and staging of patients with lung cancer. This method provides an unbiased detection strategy to establish a more precise correlation between CTC quantification and the actual burden of disease, therefore improving the accuracy of staging based on current imaging techniques. Also, by applying statistical analysis techniques and probabilistic models to the metabolic status and distribution of peripheral blood mononuclear cell (PBMC) populations 'perturbed' by the presence of CTCs, a new category of adaptive metabolic pattern biomarker (AMPB) is described and unambiguously correlated to the different clinical stages of the patients. In fact, this strategy allows for classification of different categories of disease within a single stage (stage IV) before computed tomography (CT) and positron emission tomography (PET) scans and with lower uncertainty.

  • Others:

    Author, as appears in the article.: Garcia-Algar, Manuel; Fernandez-Carrascal, Ana; Olano-Daza, Ana; Guerrini, Luca; Feliu, Neus; Parak, Wolfgang J; Guimera, Roger; Garcia-Rico, Eduardo; Alvarez-Puebla, Ramon A
    Department: Enginyeria Química
    URV's Author/s: Alvarez Puebla, Ramon Angel / Guerrini, Luca / Guimera Manrique, Roger
    Keywords: Good health and well-being
    Abstract: In this manuscript, we demonstrate the applicability of a metabolic liquid biopsy for the monitoring and staging of patients with lung cancer. This method provides an unbiased detection strategy to establish a more precise correlation between CTC quantification and the actual burden of disease, therefore improving the accuracy of staging based on current imaging techniques. Also, by applying statistical analysis techniques and probabilistic models to the metabolic status and distribution of peripheral blood mononuclear cell (PBMC) populations 'perturbed' by the presence of CTCs, a new category of adaptive metabolic pattern biomarker (AMPB) is described and unambiguously correlated to the different clinical stages of the patients. In fact, this strategy allows for classification of different categories of disease within a single stage (stage IV) before computed tomography (CT) and positron emission tomography (PET) scans and with lower uncertainty.
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 2397-768X
    Author's mail: roger.guimera@urv.cat ramon.alvarez@urv.cat luca.guerrini@urv.cat
    Author identifier: 0000-0002-3597-4310 0000-0003-4770-5756 0000-0002-2925-1562
    Record's date: 2024-11-16
    Journal volume: 2
    Papper version: info:eu-repo/semantics/publishedVersion
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Npj Precision Oncology. 2 (1): 16-
    APA: Garcia-Algar, Manuel; Fernandez-Carrascal, Ana; Olano-Daza, Ana; Guerrini, Luca; Feliu, Neus; Parak, Wolfgang J; Guimera, Roger; Garcia-Rico, Eduardo; (2018). Adaptive metabolic pattern biomarker for disease monitoring and staging of lung cancer with liquid biopsy. Npj Precision Oncology, 2(1), 16-. DOI: 10.1038/s41698-018-0059-9
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2018
    First page: Article number 16
    Publication Type: Journal Publications